Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20456976 | 1.00 | HSD11B1 (1.00) | HSD11B1HSD11B2 | |
| SCHEMBL31419780 | 1.00 | HSD11B1 (1.00) | HSD11B1HSD11B2 | |
| SCHEMBL19248200 | 1.00 | HSD11B1 (1.00) | HSD11B1HSD11B2 | |
| SCHEMBL9947970 | 0.93 | HSD11B1 (0.87) | HSD11B1HSD11B2 | |
| SCHEMBL975874 | 0.93 | HSD11B1 (0.86) | HSD11B1HSD11B2 | |
| SCHEMBL973411 | 0.92 | HSD11B1 (0.85) | HSD11B1HSD11B2 | |
| SCHEMBL974187 | 0.91 | HSD11B1 (0.84) | HSD11B1HSD11B2 | |
| SCHEMBL974022 | 0.91 | HSD11B1 (0.83) | HSD11B1HSD11B2 | |
| SCHEMBL973791 | 0.91 | HSD11B1 (0.83) | HSD11B1HSD11B2 | |
| SCHEMBL973381 | 0.90 | HSD11B1 (0.82) | HSD11B1HSD11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110009391-A1 | TETRAHYDROQUINOXALINE UREA DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | SANOFI-AVENTIS (FR) | 2011-01-13 | — | — | US | claimed |
| US-20260137659-A1 | METHODS AND COMPOSITIONS FOR TREATING GLUCOCORTICOID EXCESS | SPARROW PHARMACEUTICALS INC (US) | 2026-05-21 | — | — | US | disclosed |
| US-20260137658-A1 | METHODS AND COMPOSITIONS FOR TREATING GLUCOCORTICOID EXCESS | SPARROW PHARMACEUTICALS INC (US) | 2026-05-21 | — | — | US | disclosed |
| US-20250319072-A1 | METHODS AND COMPOSITIONS FOR TREATING GLUCOCORTICOID EXCESS | SPARROW PHARMACEUTICALS INC (US) | 2025-10-16 | — | — | US | disclosed |
| US-12329745-B2 | Methods and compositions for treating glucocorticoid excess | SPARROW PHARMACEUTICALS, INC. (US) | 2025-06-17 | — | — | US | disclosed |
| US-20240293375-A1 | METHODS AND COMPOSITIONS FOR TREATING GLUCOCORTICOID EXCESS | FIRST-CITIZENS BANK & TRUST COMPANY | 2024-09-05 | — | — | US | disclosed |
| US-20230364060-A1 | METHODS AND COMPOSITIONS FOR TREATING GLUCOCORTICOID EXCESS | FIRST-CITIZENS BANK & TRUST COMPANY | 2023-11-16 | — | — | US | disclosed |
| US-20110009391-A1 | TETRAHYDROQUINOXALINE UREA DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | SANOFI-AVENTIS (FR) | 2011-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240293375-A1 | METHODS AND COMPOSITIONS FOR TREATING GLUCOCORTICOID EXCESS | HSD11B1, HSD17B1, HSD3B1 | HSD11B1 1/4885HSD11B2 5/4885 |
| US-20250319072-A1 | METHODS AND COMPOSITIONS FOR TREATING GLUCOCORTICOID EXCESS | HSD11B1, HSD17B1, HSD3B1 | HSD11B1 1/4885HSD11B2 5/4885 |
| US-12329745-B2 | Methods and compositions for treating glucocorticoid excess | HSD11B1, HSD17B1, HSD3B1 | HSD11B1 1/4885HSD11B2 5/4885 |
| US-20110009391-A1 | TETRAHYDROQUINOXALINE UREA DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | BHMT, UGDH, NNMT | HSD11B1 4293/4885HSD11B2 4431/4885 |
| US-20230364060-A1 | METHODS AND COMPOSITIONS FOR TREATING GLUCOCORTICOID EXCESS | HSD11B1, HSD17B1, HSD3B1 | HSD11B1 1/4885HSD11B2 5/4885 |
| US-20260137659-A1 | METHODS AND COMPOSITIONS FOR TREATING GLUCOCORTICOID EXCESS | NR3C2, NR3C1, MC2R | HSD11B1 4/4885HSD11B2 7/4885 |
| US-20260137658-A1 | METHODS AND COMPOSITIONS FOR TREATING GLUCOCORTICOID EXCESS | NR3C1, NR3C2, NR5A1 | HSD11B1 5/4885HSD11B2 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.